BRAF V600E-mutant squamous cell carcinoma of the lung in patients with a history of papillary thyroid carcinoma: A three-case series

There is limited data on BRAF V600E-mutant squamous cell carcinoma (SCC). We report three cases of SCC of the lung with a history of resected papillary thyroid carcinoma (PTC), showing p40 positivity, TTF-1 negativity, and PAX8 expression. While treated as lung SCC, metastatic thyroid carcinoma was unconfirmed due to absence of PTC recurrence, clinicopathologic features consistent with primary lung origin, and unavailable archival PTC pathology. BRAF inhibitors yielded only transient responses, and outcomes were poor. These cases underscore the diagnostic and therapeutic value of multigene testing in SCC, highlighting the need to integrate detailed clinical history into precision oncology strategies.

Authors

Institutions

Publication Details

Journal
Respiratory Investigation
Published
2025-12-01
DOI
https://doi.org/10.1016/j.resinv.2025.101344
Primary Topic
Lung Cancer Treatments and Mutations
Type
article
Field-Weighted Citation Impact
0.00
Controls
|||
ALL TIME
JAN
FEB
MAR
APR
MAY
JUN
JUL
AUG
SEP
OCT
article

BRAF V600E-mutant squamous cell carcinoma of the lung in patients with a history of papillary thyroid carcinoma: A three-case series

Kazuyoshi Imaizumi, Hisashi Kako, Masashi Kondo, Yasuhiro Gotô et al.
Respiratory Investigation
Lung Cancer Treatments and Mutations
article

BRAF V600E-mutant squamous cell carcinoma of the lung in patients with a history of papillary thyroid carcinoma: A three-case series

Kazuyoshi Imaizumi, Hisashi Kako, Masashi Kondo, Yasuhiro Gotô, Yuko Oya, Sumito Isogai, Naozumi Hashimoto, Ken Akao, Ryoma Moriya, Tomohide Souma, Tetsuya Tsukamoto, Yuka Kondo
article en

Abstract

There is limited data on BRAF V600E-mutant squamous cell carcinoma (SCC). We report three cases of SCC of the lung with a history of resected papillary thyroid carcinoma (PTC), showing p40 positivity, TTF-1 negativity, and PAX8 expression. While treated as lung SCC, metastatic thyroid carcinoma was unconfirmed due to absence of PTC recurrence, clinicopathologic features consistent with primary lung origin, and unavailable archival PTC pathology. BRAF inhibitors yielded only transient responses, and outcomes were poor. These cases underscore the diagnostic and therapeutic value of multigene testing in SCC, highlighting the need to integrate detailed clinical history into precision oncology strategies.

Respiratory InvestigationVol. 64(1)
Fujita Health University (JP), Fujita Health University Hospital (JP)
Openalex Percentile: Top 44%
Lung Cancer Treatments and Mutations
AI Navigator

Ask Laika to Summarize, Analyze, and Connect papers live on the map.

Summarize Papers & Methodologies

Extract key findings, datasets, and comparative methods across publications.

Benchmark Rankings & Visual Analytics

Rank top research institutions, authors, funders, topics, and journals by Field-Weighted Citation Impact (FWCI) and paper volume with instant charts.

Connect Distant Disciplines

Bridge topological clusters on the map to find hidden collaborative intersections.

BRAF V600E-mutant squamous cell carcinoma of the lung in patients with a history of papillary thyroid carcinoma: A three-case series — Kazuyoshi Imaizumi, Hisashi Kako, et al. · Respiratory Investigation (2025) | TGRS Research Map | TGRS